Shots:
- Apotex became the first company to receive Health Canada approval for a generic equivalent of Wegovy, with Sevmia (semaglutide injection) approved for chronic weight management in adults.
- Sevmia is indicated for adults with obesity or overweight with at least one weight-related comorbidity and to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI ≥27 kg/m².
- The approval follows the recent authorization of Apo-Semaglutide Injection, expanding Apotex’s semaglutide portfolio across type 2 diabetes and chronic weight management.
- Developed in partnership with Orbicular Pharmaceutical Technologies, Sevmia supports Apotex’s strategy to improve access to high-quality, affordable semaglutide therapies in Canada.
Takeaways:
Sevmia’s approval makes Apotex the first Canadian generic challenger in Wegovy, which should increase price competition, widen access to semaglutide for chronic weight management, and put pressure on branded obesity-drug economics in Canada. [implied] Because the label also covers cardiovascular risk reduction in eligible patients, Apotex now has a stronger foothold in the growing GLP-1 market, with its semaglutide franchise spanning both type 2 diabetes and obesity indications and potentially accelerating payer interest in lower-cost alternatives.
Source: PRnewswire
